Compare LGCB & DARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LGCB | DARE |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.4M | 24.0M |
| IPO Year | 2023 | N/A |
| Metric | LGCB | DARE |
|---|---|---|
| Price | $2.00 | $2.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 58.9K | ★ 290.0K |
| Earning Date | 07-03-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $8,993,265.00 | N/A |
| Revenue This Year | N/A | $3,924.12 |
| Revenue Next Year | N/A | $8,523.64 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 5.80 | N/A |
| 52 Week Low | $1.22 | $1.61 |
| 52 Week High | $6.83 | $9.19 |
| Indicator | LGCB | DARE |
|---|---|---|
| Relative Strength Index (RSI) | 51.41 | 53.67 |
| Support Level | $1.76 | $2.16 |
| Resistance Level | $2.09 | $2.52 |
| Average True Range (ATR) | 0.11 | 0.18 |
| MACD | -0.02 | 0.04 |
| Stochastic Oscillator | 45.54 | 50.56 |
Linkage Global Inc is a cross-border e-commerce integrated service provider. It provides international e-commerce merchants, overseas brands, import and export trading enterprises, etc. with a globally selected supply chain, digital marketing, e-commerce training, international store, ERP and e-commerce software, social e-commerce and other e-commerce integrated services. The Company has two operating segments: Extend from Japan, and Other Subsidiaries from Hong Kong. The company is Committed to building a one-stop cross-border integrated service platform to make cross-border trade easier. Company operates in Japan, Hong Kong and China, with maximum revenue from Japan.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.